Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007340
Chunk: 18

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 18
---
 the closing under the agreements, we issued (A) an
aggregate of (i) 8,997 Depositary Shares to certain of the Secured Noteholders and (ii) 90,999 pre-funded warrants to purchase Depositary
Shares to certain of the Secured Noteholders, or the December 2023 Private Placement Pre-Funded Warrants, and (B) 14,177 Depositary Shares
to Melior. Between December 21, 2023 and April 1, 2025, we have issued 738,002,400 Ordinary Shares upon the exercise of December 2023
Private Placement Pre-Funded Warrants issued to the Secured Noteholders.

On December 21, 2023, we completed the closing of an underwritten public offering,
pursuant to which we issued and sold (i) 43,555 Class A units, or Class A Units, at a public offering price of $50.00 per Class A Unit,
with each Class A Unit consisting of (a) one Depositary Share, (b) one Series E warrant, or Series E Warrant, and (c) one Series F warrant,
or Series F Warrant, and (ii) 76,447 Class B units, or Class B Units, at a public offering price of $26.9999 per Class B Unit, with each
Class B Unit consisting of (a) one pre-funded warrant, exercisable for one Depositary Share, (b) one Series E Warrant, and (c) one
Series F Warrant. The aggregate gross proceeds to the Company were approximately $6.0 million. Additionally, we issued warrantsto purchase
4,800 of our Depositary Shares in connection with the offering to the underwriter, or the December 2023 Underwriter Warrants.

| 16 |

On February 26, 2024, in connection with our obligations under a license agreement
with Melior, we issued 14,177 Depositary Shares to Bukwang Pharmaceutical Co. Ltd.

On April 29, 2024, in connection
with the closing of the transaction contemplated by the license and collaboration agreement with Rapamycin Holdings, Inc. d/b/a Emtora
Biosciences, Inc., or Emtora, we issued 15,136 Depositary Shares to Emtora.

On May 24, 2024, in connection
with the transactions contemplated by certain warrant inducement letters, we issued an aggregate